Defining Predictors of RT Response to Vedolizumab in IBD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-08

Study Completion Date

2024-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify response to vedolizumab in small bowel CD using objective endpoints. Current data suggest that MR enterography may meet this unmet need. There is an additional unmet need to develop predictive models incorporating both clinical and baseline radiological and endoscopic variables with higher discriminatory performance in identifying longer term clinical remission with vedolizumab. Finally, this proposal is strengthened by the exploratory studies which may identify new proteomic biomarkers that correlate with longer term radiological response with vedolizumab reflecting its latency of response. If successful, these serum biomarkers may guide a personalized approach to the treatment of small bowel CD with vedolizumab, allowing early identification of PNR, monitoring disease activity and the pharmacodynamics of vedolizumab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

NCT02425111

Crohn's Disease

COMPLETED PHASE3

Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

NCT07093294

Crohn Disease (CD) Vedolizumab Intestinal Ultrasound +1 more

RECRUITING

Response Assessment in SB CD

NCT03646708

Small Bowel Crohn's Disease

RECRUITING

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

NCT03234907

Crohn's Disease

COMPLETED PHASE3

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512

Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease of Small Intestine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vedolizumab 300 MG Injection [Entyvio]

Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.

Group Type EXPERIMENTAL

Vedolizumab 300 MG Injection [Entyvio]

Intervention Type DRUG

Vedolizumab Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vedolizumab 300 MG Injection [Entyvio]

Vedolizumab Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Entyvio

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe disease activity small bowel CD (small bowel only or ileocecal only) visible on MRE
* Initiated on Vedolizumab with/without thiopurines or methotrexate
* ≥18 years old

Exclusion Criteria

* Pregnancy
* Age \<18
* Planned surgery prior to the first follow-up MRE
* Inability to provide informed consent.
* Perianal CD will be excluded since assessment requires performance of additional MRI of the pelvis.
* Individuals with colonic involvement other than involvement of the ascending colon and cecum.
* Inpatient scans will only be included if this is a MRE and adequate small bowel distension with appropriate contrast has been achieved
* If unable to provide informed consent
* Contraindications for MRE including chronic kidney disease that precludes contrast administration, implanted medical devices that are contraindicated for MRE.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No